Patents by Inventor Herve Perron

Herve Perron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis
    Patent number: 10981977
    Abstract: The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or is therapy.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: April 20, 2021
    Assignees: GENEURO SA, THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Hervé Perron, Julie Medina, Avindra Nath, Joseph Perry Steiner, Wenxue Li, Myoung-Hwa Lee
  • Antiretroviral drug targeting human endogenous retrovirus
    Patent number: 10894820
    Abstract: The invention relates to an antibody, a fragment or a derivative thereof, for use as an antiretroviral drug targeting a virus belonging to human endogenous retroviruses type W (HERV-W), wherein said antibody, fragment or derivative thereof is directed against HERV-W Envelope protein (HERV-W Env). The invention also relates to a composition comprising said antibody and a retroviral reverse-transcriptase inhibitory drug, for use as an antiretroviral drug targeting a virus belonging to HERV-W.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: January 19, 2021
    Assignee: GENEURO SA
    Inventors: Herve Perron, Francois Curtin, Alois Lang, Raphael Faucard, Julie Medina, Alexandra Madeira, Nadege Gehin
  • ANTI-HERV-K ENVELOPE ANTIBODY AND USES THEREOF
    Publication number: 20200308258
    Abstract: The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or is therapy.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Inventors: Hervé PERRON, Julie MEDINA, Avindra NATH, Joseph Perry Steiner, Wenxue LI, Myoung-Hwa LEE
  • Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein
    Patent number: 10752675
    Abstract: The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: August 25, 2020
    Assignee: GENEURO S.A.
    Inventors: Herve Perron, Reza Firouzi, Patrick Küry, Raphaël Faucard, Alexandra Madeira, Julie Joanou
  • Methods for alleviating symptoms of sporadic amyotrophic lateral sclerosis by neutralizing a HERV-K envelope protein using an anti-HERV-K envelope protein antibody
    Patent number: 10723787
    Abstract: The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or in therapy.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: July 28, 2020
    Assignees: GENEURO SA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Hervé Perron, Julie Medina, Avindra Nath, Joseph Perry Steiner, Wenxue Li, Myound-Hwa Lee
  • ANTI-HERV-K ENVELOPE ANTIBODY AND USES THEREOF
    Publication number: 20190345232
    Abstract: The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or in therapy.
    Type: Application
    Filed: January 19, 2018
    Publication date: November 14, 2019
    Inventors: Hervé PERRON, Julie MEDINA, Avindra NATH, Joseph Perry Steiner, Wenxue LI, Myound-Hwa LEE
  • Antiretroviral Drug Targeting Human Endogenous Retrovirus
    Publication number: 20190263895
    Abstract: The invention relates to an antibody, a fragment or a derivative thereof, for use as an antiretroviral drug targeting a virus belonging to human endogenous retroviruses type W (HERV-W), wherein said antibody, fragment or derivative thereof is directed against HERV-W Envelope protein (HERV-W Env). The invention also relates to a composition comprising said antibody and a retroviral reverse-transcriptase inhibitory drug, for use as an antiretroviral drug targeting a virus belonging to HERV-W.
    Type: Application
    Filed: March 22, 2019
    Publication date: August 29, 2019
    Inventors: Herve Perron, Francois Curtin, Alois Lang, Raphael Faucard, Julie Medina, Alexandra Madeira, Nadege Gehin
  • Therapeutic use of specific ligand in MSRV associated diseases
    Patent number: 10059758
    Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: August 28, 2018
    Assignee: GENEURO SA
    Inventors: Corinne Bernard, Alois Bernhardt Lang, Herve Perron, Jean-Baptiste Bertrand
  • COMPOUNDS FOR TREATING THE REMYELINATION BLOCKADE IN DISEASES ASSOCIATED WITH THE EXPRESSION OF HERV-W ENVELOPE PROTEIN
    Publication number: 20180066040
    Abstract: The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.
    Type: Application
    Filed: November 14, 2017
    Publication date: March 8, 2018
    Applicant: GENEURO S.A.
    Inventors: Herve PERRON, Reza FIROUZI, Patrick KÜRY, Raphaël FAUCARD, Alexandra MADEIRA, Julie JOANOU
  • THERAPEUTIC USE OF SPECIFIC LIGAND IN MSRV ASSOCIATED DISEASES
    Publication number: 20180057569
    Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.
    Type: Application
    Filed: October 26, 2017
    Publication date: March 1, 2018
    Applicant: GENEURO SA
    Inventors: Corinne BERNARD, Alois Bernhardt LANG, Herve PERRON, Jean-Baptiste BERTRAND
  • Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein
    Patent number: 9840550
    Abstract: The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: December 12, 2017
    Assignee: GENEURO S.A.
    Inventors: Hervé Perron, Reza Firouzi, Patrick Küry, Raphaël Faucard, Alexandra Madeira, Julie Joanou
  • Therapeutic use of specific ligand in MSRV associated diseases
    Patent number: 9815888
    Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 14, 2017
    Assignee: GENEURO SA
    Inventors: Corinne Bernard, Alois Bernhardt Lang, Herve Perron, Jean-Baptiste Bertrand
  • THERAPEUTIC USE OF SPECIFIC LIGAND IN MSRV ASSOCIATED DISEASES
    Publication number: 20170107274
    Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.
    Type: Application
    Filed: December 2, 2016
    Publication date: April 20, 2017
    Applicant: GENEURO SA
    Inventors: Corinne BERNARD, Alois Bernhardt LANG, Herve PERRON, Jean-Baptiste BERTRAND
  • Antiretroviral Drug Targeting Human Endogenous Retrovirus
    Publication number: 20170101461
    Abstract: The invention relates to an antibody, a fragment or a derivative thereof, for use as an antiretroviral drug targeting a virus belonging to human endogenous retroviruses type W (HERV-W), wherein said antibody, fragment or derivative thereof is directed against HERV-W Envelope protein (HERV-W Env). The invention also relates to a composition comprising said antibody and a retroviral reverse-transcriptase inhibitory drug, for use as an antiretroviral drug targeting a virus belonging to HERV-W.
    Type: Application
    Filed: May 27, 2015
    Publication date: April 13, 2017
    Inventors: Herve Perron, Francois Curtin, Alois Lang, Raphael Faucard, Julie Medina, Alexandra Madeira, Nadege Gehin
  • Therapeutic use of specific ligand in MSRV associated diseases
    Patent number: 9550824
    Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: January 24, 2017
    Assignee: GENEURO SA
    Inventors: Corinne Bernard, Alois Bernhardt Lang, Herve Perron, Jean-Baptiste Bertrand
  • COMPOUNDS FOR TREATING THE REMYELINATION BLOCKADE IN DISEASES ASSOCIATED WITH THE EXPRESSION OF HERV-W ENVELOPE PROTEIN
    Publication number: 20150218256
    Abstract: The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.
    Type: Application
    Filed: October 1, 2013
    Publication date: August 6, 2015
    Inventors: Hervé Perron, Reza Firouzi, Patrick Küry, Raphaël Faucard, Alexandra Madeira, Julie Joanou
  • THERAPEUTIC USE OF SPECIFIC LIGAND IN MSRV ASSOCIATED DISEASES
    Publication number: 20140220026
    Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.
    Type: Application
    Filed: March 21, 2014
    Publication date: August 7, 2014
    Applicant: GENEURO SA
    Inventors: Corinne BERNARD, Alois Bernhardt LANG, Herve PERRON, Jean-Baptiste BERTRAND
  • Therapeutic use of specific ligand in MSRV associated diseases
    Patent number: 8715656
    Abstract: The present invention deals with a ligand comprising each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1(SEQ ID No. 1), from 0 to 2 in CDR2(SEQ ID No. 2), from 0 to 2 in CDR3(SEQ ID No. 3), from 0 to 1 in CDR4(SEQ ID No. 4), from 0 to 4 in CDR5(SEQ ID No. 5), from 0 to 2 in CDR6(SEQ ID No. 6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: May 6, 2014
    Assignee: Geneuro SA
    Inventors: Corinne Bernard, Alois Bernhardt Lang, Herve Perron, Jean-Baptiste Bertrand
  • ENDOGENETIC RETROVIRAL SEQUENCES, ASSOCIATED WITH AUTOIMMUNE DISEASES OR WITH PREGNANCY DISORDERS
    Publication number: 20120190569
    Abstract: A genomic retroviral nucleic material, in an isolated or purified state, at least partially functional or non-functional, wherein the genome comprises a reference nucleotide sequence selected from the group including sequences of SEQ ID NOs: 1-15, their complementary sequences, and their equivalent sequences, in particular, nucleotide sequences having, for every series of 100 contiguous monomers, at least 70% and preferably at least 90% homology with the sequences of SEQ ID NOs: 1-15.
    Type: Application
    Filed: December 23, 2011
    Publication date: July 26, 2012
    Applicant: BIOMERIEUX
    Inventors: Frédéric BESEME, Jean-Luc BLOND, Olivier BOUTON, Bernard MANDRAND, Francois MALLET, Hervé PERRON
  • Method for detecting aggregate-forming circulating protein forms using an agent for aggregating said forms and an agent for capturing formed aggregates
    Patent number: 8158441
    Abstract: The present invention concerns a method for detecting aggregate-forming circulating protein forms in a biological sample of human origin that may contain said aggregate-forming circulating protein forms, characterized in that it uses a non-protein agent I producing aggregation of the circulating forms of the noninfectious proteins involved in pathological aggregation processes of the central nervous system and/or a non-protein agent II for capturing the natural aggregrates of aggregate-forming circulating protein forms or the aggregates induced by said agents I.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: April 17, 2012
    Assignees: Biomerieux S.A., Centre National de la Recherche Scientifique, Universite Claude Bernard Lyon 1
    Inventors: Sébastien Cecillon, Anthony William Coleman, Anne Eveno-Nobile, Hervé Perron, Marc Rodrigue